3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Bronchial Diseases
1
Adenocarcinoma
1
Interventions
Cisplatin
4
Etoposide
3
Carboplatin
3
etoposide phosphate
2
Paclitaxel
2
Bleomycin
2
pralsetinib
1
pembrolizumab
1
pegfilgrastim
1
Standard of Care
1
Specimen Handling
1
Respiratory Physiological Phenomena
1
Practice Guidelines as Topic
1
Platinum
1
Pemetrexed
1
Magnetic Resonance Spectroscopy
1
Injections
1
Ifosfamide
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Filgrastim
1
Biopsy
1
Aprepitant
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms, Germ Cell and Embryonal
×
pralsetinib
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts